Krystal Biotech Inc. (KRYS)

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli...

Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation, potentially boosting its global market presence and valuation. Despite KRYS's premium valuat...

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.

Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Krystal Biotech's VYJUVEK shows strong growth, with 2025 sales expected to exceed $1B, bolstered by launches in the EU and Japan. Q4 earnings beat EPS expectations but slightly missed revenue forecast...